ストックスクリーナーアプリを入手
1.26
3.82%
-0.05
プレマーケット:
1.25
-0.01
-0.79%
前日終値:
$1.31
開ける：
$1.3
24時間の取引高:
537.38K
Relative Volume:
1.33
時価総額：
$33.50M
収益：
$50,000
当期純損益:
$-49.89M
株価収益率:
-0.5888
EPS:
-2.1398
ネットキャッシュフロー:
$-31.55M
1週間 パフォーマンス:
-12.50%
1か月 パフォーマンス:
-25.88%
6か月 パフォーマンス:
-47.72%
1年 パフォーマンス:
-85.33%
1日の値動き範囲:
$1.2102
$1.3399
1週間の範囲:
$1.2102
$1.4754
52週間の値動き範囲:
$1.2102
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
名前
Inmune Bio Inc
セクター
電話
(858) 964-3720
住所
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.26 | 34.83M | 50,000 | -49.89M | -31.55M | -2.1398 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.64 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-01 | ダウングレード | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-21 | 開始されました | Alliance Global Partners | Buy |
| 2024-09-27 | 開始されました | Raymond James | Outperform |
| 2024-08-22 | 開始されました | Scotiabank | Sector Outperform |
| 2023-06-01 | 開始されました | Robert W. Baird | Outperform |
| 2022-05-24 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
| 2021-04-21 | 開始されました | B. Riley Securities | Buy |
| 2021-01-22 | 繰り返されました | Maxim Group | Buy |
| 2020-09-01 | 開始されました | BTIG Research | Buy |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Inmune Bio Inc (INMB) 最新ニュース
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study - TipRanks
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - The Manila Times
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Levels Update: Is INmune Bio Inc stock undervalued right nowMarket Sentiment Review & Daily Stock Trend Reports - baoquankhu1.vn
INmune Bio to host webinar on RDEB treatment data - Investing.com Australia
INmune Bio to Present New CORDStrom Phase III Data - TipRanks
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
INmune Bio to host webinar on RDEB treatment data By Investing.com - Investing.com Nigeria
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - The Manila Times
INmune Bio Inc. to Host Webinar on CORDStrom Treatment for Recessive Dystrophic Epidermolysis Bullosa, Highlighting New Clinical Data and Insights from MissionEB Study - Quiver Quantitative
New trial data on systemic treatment for a painful skin disease - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Aug Action: What are INmune Bio Incs earnings expectations2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Is INmune Bio Inc. stock a buy for dividend growthPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization - TipRanks
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Inmune Bio plans to seek approval of RDEB treatment in UK, US, and EU in 2026 - Epidermolysis Bullosa News
Inmune Bio announces FDA alignment on integrated Phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
Inmune Bio announces FDA alignment on integrated phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? - Asianet Newsable
INmune Bio Gains FDA Alignment On Phase 2b/3 Trial Design For Alzheimer's Drug XPro1595 - Nasdaq
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - The Manila Times
Will INmune Bio Inc. benefit from geopolitical trends2025 Market Outlook & Daily Growth Stock Investment Tips - mfd.ru
Is INmune Bio Inc. stock a value trapRate Hike & Safe Entry Momentum Tips - mfd.ru
INmune Bio submits pre-submission package for CORDStrom with MHRA - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Given Average Rating of “Reduce” by Brokerages - Defense World
Inmune Bio Inc Submitted Pre-Submission Package For Cordstrom With Uk's Mhra - TradingView
Inmune Bio Advances Cordstrom™ Towards Uk Marketing Authorization In Rdeb - TradingView
INmune Bio (INMB) Advances with Regulatory Submission for CORDSt - GuruFocus
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - The Manila Times
Rare 'butterfly skin' disease therapy takes key step toward UK review - Stock Titan
Death Cross: Whats the profit margin of INmune Bio IncJuly 2025 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
Smart Money: Will INmune Bio Inc benefit from geopolitical trendsJuly 2025 Trends & Consistent Profit Trading Strategies - baoquankhu1.vn
Retail Surge: What is the earnings history of INmune Bio Inc2025 Valuation Update & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Movers: Will INmune Bio Inc benefit from geopolitical trendsInsider Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating - TipRanks
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies By Investing.com - Investing.com Australia
New Highs: Can ProShares Trust ProShares UltraShort SmallCap600 expand into new marketsDollar Strength & Reliable Intraday Trade Plans - baoquankhu1.vn
INmune Bio outlines 2026 regulatory path in shareholder letter - TipRanks
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
INmune Bio (INMB) Reflects on Key Progress and Financial Stabili - GuruFocus
INmune Bio (INMB) Reflects on Key Progress and Financial Stability in 2025 - GuruFocus
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies - Investing.com
INmune Bio, Inc. Provides Investor Update on 2025 Progress and Future Regulatory Plans - Quiver Quantitative
Sell Signal: Will Reading International Inc benefit from geopolitical trends2025 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Rallies: What is the earnings history of INmune Bio IncMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Is INmune Bio Inc. trading at a discountDay Trade & Reliable Price Breakout Alerts - bollywoodhelpline.com
Take Profit: Is Varex Imaging Corporation still a buy after recent gains - baoquankhu1.vn
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
Inmune Bio Inc (INMB) 財務データ
収益
当期純利益
現金流量
EPS
2.25%
0.47%
大文字化:
|
ボリューム (24 時間):